TITLE

Antipsychotics and newborns

AUTHOR(S)
Kondro, Wayne
PUB. DATE
August 2011
SOURCE
CMAJ: Canadian Medical Association Journal;8/9/2011, Vol. 183 Issue 11, pE721
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that Canada's Health Canada is following the U.S. lead and revised labelling requirements for a class of antipsychotic drugs being used during pregnancies.
ACCESSION #
67138088

 

Related Articles

  • Unauthorised products warning in Canada.  // Reactions Weekly;2/27/2010, Issue 1290, p4 

    The article reports on a warning issued by Health Canada to customers about unauthorised products sold under the "OM Fusion Distributors LLC" label stating that the products may cause life threatening reactions.

  • Liver failure linked to use of atypical antipsychotics?  // Reactions Weekly;Feb2015, Vol. 1537 Issue 1, p6 

    The article presents a safety review by Health Canada on the association of using atypical antipsychotics to liver failure.

  • New table helps generic co.'s keep safety labelling up to date.  // Reactions Weekly;3/16/2013, Issue 1444, p5 

    The article reports that the Health Canada launched a table on its website focused on informing generic drug manufacturers about the safety labelling changes to the Product Monographs, pharmaceutical brand.

  • Health Canada requests clarity in botulinum toxin naming.  // Reactions Weekly;2/2/2013, Issue 1437, p3 

    The article reports that Health Canada has asked the manufacturers of botulinum toxin products to revise their labelling to reflect that each product has its own potency and is not interchangeable with other botulinum toxin products.

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;5/12/2012, Issue 1401, p4 

    This section offers news briefs related to the pharmaceutical industry, including the announcement by Health Canada that the labelling for Cipralex has been updated to warn of a dose-related risk of QT interval prolongation and the addition by Celgene Inc. of new safety information to the...

  • BPH drugs may increase high-grade prostate cancer risk.  // Reactions Weekly;3/24/2012, Issue 1394, p1 

    The article reports on an advice issued by Health Canada that the Canadian labels for brand name formulations of finasteride (Proscar, Propecia) and dutasteride [Avodart, Jalyn (dutasteride/tamsulosin)] were updated to include the associated risk of high-grade prostate cancer.

  • Homeopathic products: labelling changes in Canada.  // Reactions Weekly;Aug2015, Vol. 1564 Issue 1, p3 

    The article reports that Health Canada will introduce labelling changes for nodose products and homeopathic cough, cold and flu products for children aged 12 years or younger.

  • Info on paediatric drug safety released by Health Canada.  // Reactions Weekly;1/28/2012, Issue 1386, p3 

    The article deals with the reports received by Health Canada regarding cardiometabolic adverse events suspected of being related to the use of second-generation antipsychotics in children and adolescents aged 18 years and below.

  • Health Canada accepts Sunovion's NDS for schizophrenia therapy.  // PharmaWatch: CNS;Oct2011, Vol. 10 Issue 10, p15 

    The article reports on the announcement of Sunovion Pharmaceuticals Canada Inc. that its new drug submission (NDS), Lurasidone HCl, has been accepted by Health Canada. The company's NDS is for the treatment of adult patients with schizophrenia. The drug is an atypical antipsychotic agent with a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics